加载中
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
常规交易时段
US$2.825
−US$0.085 · -2.92%
盘中时间采用ET。市场数据可能有所延迟。
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
日内区间
当前US$2.825
52周区间
当前US$2.825
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
78
低估
情绪
50
多空交织
风险
42
风险偏高
动量
73
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
日内区间
当前US$2.825
52周区间
当前US$2.825
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3511.3万 USD | 255.7万 USD | — | — | — |
| 销货成本 | 625.7万 USD | 79.7万 USD | — | — | 189.2万 USD |
| 毛利 | 2885.6万 USD | 176万 USD | — | — | −189.2万 USD |
| 研究与开发 | 7222.3万 USD | 8164.3万 USD | 7201.7万 USD | 6105.8万 USD | 4875.5万 USD |
| 销售、一般及管理费用 | 4351.6万 USD | 6151.8万 USD | 3550.5万 USD | 2702万 USD | 2470.2万 USD |
| 营业费用 | 1.16亿 USD | 3816.1万 USD | 1.08亿 USD | 8756.9万 USD | 7345.7万 USD |
| 利息收入 | 457.6万 USD | 576.9万 USD | 458.2万 USD | 21.9万 USD | 1万 USD |
| 利息支出 | 887.6万 USD | 876.8万 USD | 577.7万 USD | 399.3万 USD | 364.2万 USD |
| 折旧和摊销 | 127.7万 USD | 79.6万 USD | 41.9万 USD | 51.3万 USD | 189.2万 USD |
| 营业利润 | −8688.3万 USD | −3640.1万 USD | −1.08亿 USD | −8756.9万 USD | −7534.9万 USD |
| 净利润 | −7919.9万 USD | −3745万 USD | −1.01亿 USD | −9386.7万 USD | −8869.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.50
上涨空间 307.08%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月28日 | 1:30 | — | — |
股票拆分 | 2019年3月14日 | 1:6 | — | — |
已生效 2025年4月28日
1:30
已生效 2019年3月14日
1:6
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1050.15万0.00%2.3万亿 USD0.03%US$381.43-0.13%
iShares Russell 2000 ETFIWM627.14万0.01%787.4亿 USD0.19%US$277.87-0.39%
Vanguard Extended Market ETFVXF414.08万0.00%954亿 USD0.05%US$233.63-0.59%
Vanguard Russell 2000 ETFVTWO187.66万0.01%180亿 USD0.06%US$112.24-0.37%
iShares Micro-Cap ETFIWC77.24万0.06%13.17亿 USD0.60%US$181.83-0.64%
ALPS Medical Breakthroughs ETFSBIO36.37万0.19%1.91亿 USD0.50%US$53.77-2.31%
Avantis U.S. Small Cap Equity ETFAVSC31.01万0.01%30.82亿 USD0.25%US$70.05+0.10%
Vanguard Russell 2000 Value ETFVTWV30.26万0.02%14亿 USD0.06%US$186.04+0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
